Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system
CA 2379115 C · Owner: The Regents Of The University Of California · Inventors: Ow, David W.; Thomason, Lynn; Calendar, Richard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides methods for obtaining specific and stable integration of nucleic acids into eukaryotic cells. The invention makes use of sitespecific recombination systems that use prokaryotic recombinase polypeptides such as the .PHI.C31 integrase, that can mediate recombination between the recombination sites, but not between hybrid recombination sites that are formed upon the recombination. Thus, the recombination is irreversible in the absence of additional factors. Eukaryotic cells that contain the recombinase polypeptides, or genes that encode the recombinases are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 21, 2000 and granted April 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 21, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 21, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.